New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
09:04 EDTGPRE, X, IACI, ESRX, AEGR, BWLD, AMGN, ZLTQ, SODA, S, UAL, DWA, TWTR, GRMN, HESOn The Fly: Pre-market Movers
HIGHER: Twitter (TWTR), up 25% after better than expected Q2 earnings results, upgraded at UBS, BofA Merrill Lynch and CRT Capital... Hess (HES), up 4.6% after reporting better than expected Q2 adjusted EPS, boosting its share buyback and announcing its intention to pursue the formation and initial public offering of a master limited partnership... United Continental (UAL), up 2.8% following upgrade to Overweight at JPMorgan. UP AFTER EARNINGS: Sprint (S), up 3.3%... Garmin (GRMN), up 9.4%... ZELTIQ (ZLTQ), up 24%... Aegerion (AEGR), up 14%... U.S. Steel (X), up 16%... Express Scripts (ESRX), up 3%... Amgen (AMGN), up 4.6%... SodaStream (SODA), up 8%. LOWER: DreamWorks Animation (DWA), down 11.8% after worse than expected Q2 loss, disclosing SEC investigating 'Turbo' writedown... IAC Interactive (IACI), down 3.4% after Q2 results miss expectations, Tutor.com unit acquires The Princeton Review. DOWN AFTER EARNINGS: Buffalo Wild Wings (BWLD), down 8.4%... Green Plains (GPRE), down 3.3%.
News For TWTR;S;HES;DWA;SODA;GRMN;UAL;ZLTQ;AEGR;X;AMGN;ESRX;GPRE;BWLD;IACI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
April 22, 2015
07:29 EDTAMGNAmgen estimates and price target raised at UBS
Subscribe for More Information
07:12 EDTHESHess Corp. initiated with a Neutral at Nomura
Subscribe for More Information
06:03 EDTAMGNAmgen price target raised to $192 from $187 at Piper Jaffray
Subscribe for More Information
06:01 EDTSGoogle could launch wireless service today, WSJ reports
Subscribe for More Information
April 21, 2015
19:06 EDTAMGNOn The Fly: After Hours Movers
Subscribe for More Information
17:07 EDTAMGNAmgen shares higher by 2.69% after Q1 results, guidance
16:04 EDTAMGNAmgen raises FY15 EPS view to $9.35-$9.65 from $9.05-$9.40, consensus $9.32
Narrows FY15 revenue view to $20.9B-$21.3B from $20.8B-$21.3B, consensus $20.98B.
16:02 EDTAMGNAmgen reports Q1 EPS $2.48, consensus $2.10
Reports Q1 revenue $5.03B, consensus $4.91B.
16:00 EDTTWTROptions Update; April 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1c to 21.53 Option volume leaders: AAPL TSLA TWTR GILD FB PBR AMZN C KMI KO VZ MCD according to Track Data.
15:28 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
15:23 EDTUALUnited Continental April weekly volatility elevated into Q1 and outlook
United Continental April weekly call option implied volatility is at 64, May is at 45, June is at 41, September is at 40; compared to its 26-week average of 43 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 22.
13:51 EDTAMGNEarnings Watch: Amgen's Enbrel, Neulasta sales key for Q1 results
Amgen (AMGN) is scheduled to report first quarter earnings after the market close on Tuesday, April 21 with a conference call scheduled for 5:00 pm ET. Amgen, a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases. EXPECTATIONS: Analysts are looking for earnings per share of $2.10 on revenue of $4.91B, according to First Call. The consensus range for EPS is $1.91-$2.25 on revenue of $4.62B-$5.13B. LAST QUARTER: Amgen reported fourth quarter EPS of $2.16 against estimates of $2.05 on revenue of $5.33B against estimates of $5.2B. With its Q4 report, Amgen also reiterated its fiscal year EPS view of 9.05-$9.40, on revenue of of $20.8B-$21.3B. Total product sales increased 8% for Q4 versus Q4 of 2013. The increase was driven primarily by Enbrel, Neulasta, Prolia, XGEVA and Vectibix .Growth for the quarter was due primarily to higher unit demand, and to a lesser extent, price. Product sales increased 6% for the full year driven by strong performance across the portfolio. STREET RESEARCH: On March 23, Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen, Eli Lilly (LLY), and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares. On March 16, RBC Capital said it believes that data presented by Amgen on its evolocumab drug for hyperlipidemia.was "very positive." The firm expects the drug to be approved in late summer. It predicts that revenue from the drug will ramp modestly and steadily, and then accelerate after positive studies of the drug's effects are released in 2017. RBC Capital estimates that worldwide revenue from the drug will peak at $2.5B+. It keeps an Outperform rating on Amgen. PRICE ACTION: Amgen shares are higher by around 6% since its last earnings report on January 27, and are up 1.25% to to $168.06 in afternoon trading ahead of Tuesday's earnings report.
09:37 EDTTWTRActive equity options trading on open
Subscribe for More Information
07:36 EDTSU.S. mobile cariers could be pressured from new data plans, WSJ says
Subscribe for More Information
05:55 EDTTWTRTwitter starts selling tickets to sporting events, Re/code reports
Subscribe for More Information
April 20, 2015
16:01 EDTTWTROptions Update; April 20, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 21.52. Option volume leaders: AAPL VZ PBR TWTR TSLA TWTR NFLX MCP FB AMZN AA C according to Track Data.
12:59 EDTTWTRTwitter revamps Direct Messaging
In a blog post Twitter said: "Direct Messages are the best way to take your public Twitter conversations private. Today, we’re changing how direct messaging works so that it’s even easier for you to communicate one-to-one or with a chosen group of people, anywhere in the world." Changes include: A setting that allows you to receive Direct Messages from anyone, even if you don’t follow them. Updated messaging rules so you can reply to anyone who sends you a Direct Message, regardless of whether or not that person follows you. A new Direct Message button on profile pages on Android and iPhone. You’ll see it on the profiles of people you can send Direct Messages to. Reference Link
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
07:19 EDTTWTRTwitter remains under-owned into Q1 results, says Deutsche Bank
Deutsche Bank says that while the set-up for shares of Twitter into the Q1 earnings report isn't as favorable as last quarter, the stock remains under-owned relative to most large cap Internet stocks. Deutsche notes its channel checks on Twitter have been "solid" all quarter around improving monetization trends. The firm sees "plenty" more upside for shares of Twitter and keeps a Buy rating on the name with a $65 price target.
April 19, 2015
17:43 EDTDWADreamWorks CEO downplays Chinese takeover speculation, Variety says
In an interview with Variety at the Beijing International Film Festival, DreamWorks (DWA) CEO Jeffrey Katzenberg said he does not believe the company is headed towards a takeover by a Chinese firm. "We are a minority owner in a joint venture here, and I think that is the most successful structure to do business here in China today... We’re very comfortable with that arrangement," said Katzenberg. Variety notes that there was speculation late last year of takeover talks with Alibaba (BABA) or Wanda. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use